Aiforia honors two AI pioneers in digital pathology at the 37th European Congress of Pathology

Aiforia Technologies Plc, Press Release, September 8, 2025, at 3:00 p.m. EEST

Aiforia Technologies awards two AI pioneers, Professor Angelo Paolo Dei Tos and Professor Catherine Guettier, for their exceptional contributions to advancing AI in clinical diagnostics. The first-ever AI Navigator award ceremony is taking place at the 37th European Congress of Digital Pathology, currently underway in Vienna, Austria.

Artificial intelligence is reshaping the future of healthcare, with pathology at the forefront of this transformation. Integrating AI into clinical pathology workflows is a critical step towards addressing the global shortage of pathologists and improving patient care. By automating time-consuming tasks and reducing subjectivity, AI enhances both the efficiency and accuracy of pathology workflows. However, while technology and AI itself have immense potential, real progress is driven by individuals who recognize AI's value in pathology, take a step forward, and navigate the change. The Aiforia AI Navigator award honors these individuals.

Angelo Paolo Dei Tos is a Professor of Pathology at the University of Padova, Director of the Department of Integrated Diagnostics at Azienda Ospedale-Università Padova, and Dean at the University of Padova School of Medicine in Italy. A couple of years ago, the hospitals in the Veneto region launched a large-scale digitalization project to integrate AI in pathology to improve efficiency, accuracy, and consistency in routine diagnostics. Aiforia’s clinical AI models are now used to support prostate, breast, and lung cancer diagnostics. Professor Dei Tos has played a central role at the heart of this transition, leading with a strong vision and showing the way forward.

Catherine Guettier is an Emeritus Professor of Pathology at the University of Paris Saclay in France, where she led pathology education for over 15 years. Professor Guettier also led pathology departments at several hospitals within Assistance Publique-Hôpitaux de Paris (AP-HP). She is a true early adopter of AI in digital pathology in France, where AP-HP has implemented Aiforia’s clinical AI models for screening prostate cancer biopsies.

“Aiforia works every day on creating the best possible tools for medical professionals worldwide. However, bringing these solutions into clinical practice would not be possible without individuals who pave the way for more precise diagnostics. The work of these AI Navigators exemplifies the vital collaboration between AI developers and clinical practitioners in driving innovation in healthcare,” says Jukka Tapaninen, CEO of Aiforia.

Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/

Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

About Aiforia 

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions already deployed, Aiforia is making a significant impact on pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient. 

Find out more at www.aiforia.com